Background. Using accurate and easy to use rapid antigen detection tests (RADTs) to identify group A beta-haemolytic Streptococci (GABHS) sore throat infections could reduce unnecessary antibiotic prescribing and antimicrobial resistance. Although there is no international consensus on the use of RADTs, these kits have been widely adopted in Finland, France and the USA. Yet in the UK, the Clinical Knowledge Summaries, that provide the main online guidance for GPs, discourage RADTs use, citing their poor sensitivity and inability to impact on prescribing decisions in acute sore throat infections.
Introduction
Although 82% of acute sore throats resolve in 1 week 1 and are primarily viral in aetiology, 64% of cases presenting to UK GPs are prescribed antibiotics. 2 Group A beta-haemolytic Streptococci (GABHS) cause 5-10% of adult sore throats. 3 Current therapeutic and diagnostic strategies aim to identify those at greatest risk of bacterial infection.
Antibiotics decrease symptom duration and incidence of subsequent complications associated with GABHS sore throat infections. 1 Most UK GPs prescribe empirically for sore throat without definitively identifying cases caused by GABHS. 4 Definitive diagnosis of GABHS sore throat infections is routinely performed by throat swab culture (gold standard test), yet the submission rates of throat swabs by UK GPs is known to vary significantly between general practices. 5 Furthermore, culture delays diagnosis for at least 18-72 hours; and therefore treatment must be postponed awaiting laboratory results, or based on clinical characteristics present at patient consultation. 6 The use of rapid point of care tests for GABHS offers an alternative to culture or empirical antibiotics. Rapid antigen detection tests (RADTs) provide results while a patient waits in the GPs surgery and decisions regarding treatment can be based on objective evidence. RADTs have the potential to cut down consultation times, reduce unnecessary antibiotic treatment and eliminate laboratory involvement.
Although there is no international consensus on RADT use, these kits have been widely adopted in Finland, France and the USA. 7 Yet in the UK, Clinical Knowledge Summaries, that provide the main online guidance for GPs, discourage the use of RADTs, citing their poor sensitivity and inability to impact on prescribing decisions in acute sore throat. 8 Previous research has reported RADTs' reliability is variable and often inadequate when compared to carefully performed culture. 9 Numerous clinical studies have reported the percentage of GABHS infections that RADTs can detect, which varies from 48% to 98.9%. 10 These discrepancies can be attributed to differences in study populations (spectrum bias), sampling techniques, culture methods and variations attributable to the personnel performing the tests. [10] [11] [12] [13] To ensure that RADTs are evaluated objectively, a standardized in vitro method using known concentrations of GABHS would remove the inherent biases associated with these clinical studies. 6, 12, [14] [15] [16] [17] [18] This investigation is part of a multicentred PRImary care Streptococcal Management (PRISM) study, focusing on the most appropriate management strategy for determining acute sore throat infections in primary care. The purpose of this study was to evaluate the ease of use and in vitro accuracy (sensitivity and specificity) of the five most commonly used RADTs in Europe.
Methods

Rapid antigen detection kits
The kits tested represented the most commonly used kits in Europe, the most widely available in the UK and those that performed reasonably in a previous study. 19 The (Fig. 1) .
Sample size for kit sensitivity testing Previous studies have shown that some RADTs are able to detect (sensitivity) between 80 and 90% of GABHS infections. 10 Assuming that the best RADT in this study would achieve sensitivity of 85-95% and to estimate with 95% confidence interval (CI) that the sensitivity of an RADT was within ±5% (i.e. to be confident that the sensitivity was not <80%, which would be less useful clinically), 1460-3920 samples were required for all five RADTs.
Sensitivity testing: ability to detect GABHS We used four Streptococcus pyogenes strains associated with clinical sore throat infections from the National Collection of Type Cultures (NCTC) (HPA, Colindale, UK). Streptococcal dilutions ranging from 10 2 up to 10 8 colony-forming units (CFU)/ml were tested against RADTs in duplicate (see detailed method Appendix 1). To mimic conditions used to undertake RADTs in a GP surgery, each streptococcal dilution was administered as a 100-ll aliquot onto a swab and these swabs were then used to perform the RADTs (as per the manufacture's instructions).
These trials showed that all RADTs detected GABHS at 10 7 CFU/ml, while some kits failed to detect Streptococci at concentrations <10 6 CFU/ml. These tests were duplicated to ensure accuracy. Subsequently each S. pyogenes stock solution was adjusted to achieve four dilutions of GABHS within this range: 2.5 Â 10 6 , 5 Â 10 6 , 7.5 Â 10 6 and 10 Â 10 6 CFU/ml. Each RADT was tested 20 times using the swab technique outlined above, at each dilution, with four GABHS strains (320 tests per RADT). The final result for each RADT investigation was interpreted in conjunction with the manufacture's instructions: positive ( Fig. 1) , slightly positive, negative or invalid.
Specificity testing: assessment of false positives due to commensal flora A panel of 23 commensal control strains normally found in the throat were obtained from the NCTC, the American Type Culture Collection (Manassas, VA) and the Family Practice-an international journal National Collection of Pathogenic Fungi (HPA, Bristol, UK) (Appendix 1). Strains were evaluated in seven test solutions, which included several organisms from similar or identical genera. The concentrations of these organisms were adjusted to represent the upper limits often found in clinical samples, with each organism equal to 10 7 CFU/ml. [20] [21] [22] [23] Each RADT was tested 10 times, with seven commensal groups (70 tests per RADT).
RADT ease of use
Ten GPs/practice nurses were recruited to evaluate the ease of use of each RADT. Four of the five RADTs were randomly allocated to each GP/practice nurse for evaluation and each RADT was performed four times. During the evaluations, each GP/practice nurse recorded the start and finish time and the time taken to read the kit instructions. A five-point Likert scale was used to assess ease of use for each RADT, instruction and interpretation of results.
Kit ease of use was additionally assessed in a laboratory setting by a biomedical scientist and consultant microbiologist-evaluating 10 characteristics of each RADT (Table 2 ). This assessment evaluated RADT packaging, shelf life, test procedure, controls, interpretation and timing of results. RADT instruction inserts were assessed on six main features: layout, font size, general clarity, stand-alone clarity of visual instructions, clarity of instructions for determining final results and inclusion of all pertinent information (i.e. how to perform and interpret a test). These features were graded from very poor to excellent as determined by the evaluators. Each test kit could score a maximum total of 22 points. Price per test (2008) was calculated, excluding company discounts for bulk purchases.
Results
Sensitivity results: ability to detect GABHS All the test kits performed better with increasing concentration of GABHS (Fig. 2) . All RADTs were positive at the highest concentration of GABHS of 10 Â 10 6 CFU/ml, while at lower concentrations of GABHS, the kits varied in their ability to give positive results. At a GABHS concentration of 10 Â 10 6 CFU/ ml, the OSOM and IMI Test Pack detected 95% of the test samples as positive, while Strepatest detected 79% (95% CI: 67-85%), Quickvue 70% (95% CI: 59-80%) and Clearview 62% (95% CI: 51-72%). The Strepatest, Quickvue and Clearview were all at least 15% less sensitive than OSOM and IMI Test Pack at all concentrations of GABHS. Each strain of GABHS caused only minor fluctuations in RADT sensitivity, verified by combining results for all RADTs and all GABHS concentrations. Detailed results are available in Appendix 2.
Specificity results: ability not to give false positives with commensal flora None of the RADTs gave any false positives when tested 10 times with each commensal group. Thus, the specificity of each RADT was 100% (95% CI: 72-100%).
Ease of use: suitability of RADTs for general practice
Since the study evaluated a selection of cassette and dipstick formats, all the kits had different characteristics, with each RADT having a variety of strengths and weaknesses (Tables 1, 2 and 3) . Kits were assessed in both the clinical and the laboratory setting.
Ease of use: clinical setting
Results of the GP/practice nurse evaluations are outlined in Table 1 . Scored using the Likert scale (1 = best and 5 = worst), the GP/practice nurse evaluations indicated that the Clearview cassettes were the most acceptable RADT in a clinical setting, awarding this kit a mean score of 2.10. However, this score was closely followed by two dipstick kits-the OSOM kit with a mean score of 2.40 and Quickvue kit with a mean score of 2.70. Notably, the IMI Test Pack was given a mean score of 3.60, which some GPs/practice nurses attributed to the fact that this kit 'had three reagents' and 'disliked having a third bottle' when compared to the other kits. Overall, the Streptatest was the least acceptable kit, with a mean score of 4.20 (Table 1) .
Ease of use: laboratory setting Overall, the OSOM kit was found to have the shortest shelf life and contained the most tests per kit (n = 50) (Tables 2 and 3 ). This may be important if surgeries are undertaking less than one test per week, as the tests may not be used before the expiry date.
While conducting the laboratory investigation, one finding reiterated the comments of the GPs/practice nurses from the clinical setting-that the IMI Test Pack needed an additional sample extraction step when compared to the other RADTs. Although this step only involved one additional extraction reagent and added only seconds onto the total test procedure, it was a notable difference when compared to the other kits.
The laboratory ease of use investigation noted that the IMI Test Pack had an end point, which could be read at between 5 and 10 minutes, with the availability of the final results confirmed by a novel 'end of assay window' (Fig. 1) . The other four kits had timed The assessment of five RADTs for the detection of GABHS based on general characteristics and the agreed combined opinion of a biomedical scientist and consultant microbiologist. *Cassttes; all other RADTs were dipsticks.
Family Practice-an international journal end points at 5 minutes, with two of the four kit instructions stating it was essential to read results at 5 minutes. Based on these differences, the flexibility of reading the end point for the IMI Test Pack was deemed the easiest format for routine clinical practice. The Clearview and IMI Test Pack were cassette formats ( Fig. 1) and it was noted that these RADTs were provided in large boxes when compared to the dipstick RADTs. This could present a storage problem for GP surgeries, particularly those practices with minimal storage space or those storing numerous RADT kits.
The cassette formats were preferred to the dipsticks, as they were easier to handle and discard. All test reagents were absorbed into the cassette test device, thus eliminating the hazard of test reagent spillages, a clear advantage for any point of care testing kit.
Overall, the IMI Test Pack achieved the highest score for general ease of use, as assessed in the laboratory, totalling 18 of 22 points (Table 1) . Streptatest and Clearview scored 15 points, Quickvue Dipstick scored 14 points and OSOM scored 13. Overall, the two cassette formats achieved the highest scores, when compared to the dipsticks.
Clarity of kit instructions and price per test
The instruction clarity of the other RADTs is outlined in Table 2 , along with price per test. Notably, there was no standard format used by the RADT manufacturers and, consequently, the quality of the kit instructions varied between RADTs. Streptatest was felt to have the best instructions overall, clear and simple, with a logical layout, while the IMI Test Pack was a close second, losing marks on small font size and the inclusion of too much information.
Overall, OSOM was the most expensive and judged to have the poorest instruction insert. Streptatest was the cheapest kit, with the best instruction clarity. The IMI Test Pack performed well overall, marred only by price per test. Clearview was the second cheapest RADT, with an average instruction manual. Notably, the difference in price per test was >3-fold, with Streptatest the cheapest at £1.38 and OSOM the most expensive at £3.46.
Discussion
Statement of principle findings
In this in vitro study, the OSOM and IMI Test Pack were 15% more sensitive (detected 15% more positive samples) than Strepatest, Quickvue and Clearview at all concentrations of GABHS. The OSOM kit detected more strains of GABHS at lower concentrations, when compared to the IMI Test Pack. Although the OSOM kit performed well in the ease of use evaluations, this kit was the most expensive and had very poor instructions. The IMI Test Pack outperformed all other kits in the laboratory ease of use evaluations, yet in the clinical setting an additional processing step resulted in mixed opinions regarding the kits acceptability. None of the RADTs gave any false-positive results with the commensal flora [specificity 100% (95% CI: 72-100%)]. Variation in GABHS strain type had little effect on RADT sensitivity, while increasing streptococcal concentrations improved the sensitivities of all kits.
Strengths of the study
Throat swab culture is an inherently inconsistent technique, 12 ,14 yet many clinical validation studies continue to evaluate the performance of RADTs against throat swab culture. Our in vitro study removed the sampling bias associated with many clinical studies, 13 by using precise GABHS concentrations and directly comparing the performance of each RADT.
The prevalence of acute throat infections is known to be higher in children. 8 Although our study did not evaluate the kits with clinical samples, our results provide information on RADT accuracy that is generalizable for the whole population-children and adults alike. With the prevalence of GABHS higher in children, it is likely the positive predictive value of the RADTs evaluated in this study will be higher in children than in adults. This will be investigated further in the PRISM study clinical trials.
The ease of use assessments were conducted in both the clinical and the laboratory settings and included the opinions of GPs/practice nurses, a biomedical scientist and a consultant microbiologist. This method was employed to ensure that all the unique kit characteristics were assessed from very different viewpoints, thereby reducing bias, while verifying RADT acceptability for use in the clinical practice setting.
Weaknesses of the study The GABHS strains used for sensitivity testing were chosen because of their association with sore throat episodes and included two mucoid strains. Testing more strains of GABHS may have altered our sensitivity findings; however, this seems unlikely, given that the four very different strains included in this study had little impact on RADT sensitivity. This study was undertaken by a biomedical scientist with laboratory training, as we wanted to minimize any user bias in our method. Previous research has shown that the professional skills of the person performing RADTs can affect their sensitivity. 24 Consequently, the accuracy of these tests may be affected when performed by untrained personnel in a general practice setting. Furthermore, this issue may be greater for those kits with poorer kit instructions.
About 20% of patients with sore throats are infected with group C or G Streptococci. 25 Investigating sore throat infections with highly specific RADTs will result in cases of group C and G infections being undiagnosed and untreated. The significance and clinical relevance of this issue will be investigated further in phase two of the PRISM study.
Comparison with existing literature
Only one similar in vitro study has been identified, a French language paper by Charlier-Bret et al. 19 Our findings were in line with this study, confirming that RADT sensitivity typically falls between 10 5 and 10 7 CFU/ml. Charlier-Bret et al. also assessed RADT ease of use, commenting that overall, all kits were easy to use, but identifying key kit features as the presence of controls and the storage of kits at 4°C or ambient temperature. These characteristics were not key features during our assessments since all five RADTs had controls and could be stored at ambient temperature. Overall, Charlier-Bret et al. evaluated four of the five kits assessed in our study, reporting the most sensitive RADT as the IMI Test Pack, followed in decreasing sensitivity by Streptatest, Quickvue Dipstick and Clearview. The OSOM kit was not evaluated.
Meaning of the study: implications for clinicians or policymakers In our opinion, the IMI Test Pack is the most appropriate for use by primary care staff since it not only has a high sensitivity and specificity but also comes in an easy to use cassette pack that can be disposed of easily and has very good kit instructions. The OSOM kit would also be accurate enough for use in primary care and was found to be 38% (95% CI: 27-48%) more sensitive at the lowest GABHS concentration when compared to the IMI Test Pack kit. However, previous experience has shown that swabs taken by experienced clinicians and nurses in general practice routinely achieve concentrations >5 Â 10 6 CFU/ml (D Mant, personal communication). Consequently, the IMI Test Pack is the best RADT on the basis of value for money and ease of use. However, it is important to note that the reliability of this test will depend on the quality of the throat swab samples. Therefore, instructions on how to take a sample may be as important as the RADT instructions currently provided with each kit.
The cost of each RADT is a barrier for their use in the health systems, especially for those doctors working in primary care who do not pay for laboratory diagnostic tests.
If health care providers wish to encourage the use of RADTs in primary care in similar environments, they will need to reimburse physicians for their use. This may well be a cost-effective policy if RADTs reduces antibiotic prescribing. However, this needs to be determined in a cost-effective model, with current RADTs kits, staff and antibiotic costs. In the second stage of the PRISM study, RADTs will be compared to other management strategies for acute sore throat.
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